Check out our latest clinical commentary in Gynecologic Oncology, where we examine how biomarker testing is transforming the care of patients with gynecologic cancers. Precision medicine is unlocking new possibilities through innovations like next-generation sequencing (NGS), liquid biopsy, tumor-agnostic therapies, and molecular stratification—but the pace of progress also brings practical challenges.To fully realize the potential of biomarker-driven care, we need clear clinical pathways, equitable access, and stronger education for providers and patients alike. Without them, we risk missing key opportunities to deliver the most effective, personalized treatment possible.

• Download

Published in: Gynecologic Oncology